PMID- 37652111
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20231216
IS  - 1535-6280 (Electronic)
IS  - 0146-2806 (Linking)
VI  - 49
IP  - 1 Pt B
DP  - 2024 Jan
TI  - Transcatheter Edge-to-Edge Repair for Tricuspid Regurgitation-A Systematic Review 
      and Meta-Analysis.
PG  - 102055
LID - S0146-2806(23)00472-3 [pii]
LID - 10.1016/j.cpcardiol.2023.102055 [doi]
AB  - Transcatheter edge-to-edge repair (TEER) has emerged as a widely accepted 
      procedure for tricuspid regurgitation (TR) as gauged by echocardiographic 
      parameters and clinical outcomes. Our study aims to assess TR severity and other 
      echocardiographic outcomes in patients undergoing TEER with TriClip, MitraClip, 
      and PASCAL devices. A literature search of 5 databases was performed until 1st 
      June 2023. Randomized controlled trials (RCTs) or observational studies with 
      moderate to severe (grade III-V) TR patients undergoing isolated TEER were 
      considered eligible. Echocardiographic, and quality of life determining outcomes 
      such as improvement in TR severity grade >/=3, New York Heart Association (NYHA) 
      class >/=3, procedural success, 6-minute walking distance (6MWD), and adverse 
      outcomes were analyzed. Grade assessment was performed and studies were assessed 
      for risk of bias and publication bias. We included 15 studies (14 observational 
      and 1 RCT) in our paper. Analysis revealed a substantial reduction in TR volume 
      (P < 0.00001), TR grading (P < 0.00001), tricuspid annular diameter (P < 
      0.00001), proximal isovelocity surface area radius (P < 0.00001), effective 
      regurgitant orifice area (P < 0.00001), and improvement in NYHA class (P < 
      0.00001) at 30 days from baseline, postprocedurally. A significant increase in 
      6MWD at 1 year (P = 0.001) was also recorded. No significant differences in left 
      ventricular ejection fraction (P = 0.87), fractional area change (P = 0.37), or 
      tricuspid annular plane systolic excursion (P = 0.76) were observed. TEER 
      procedural success was 97%. TEER produced a significant reduction in TR grade and 
      volume, NYHA class, 6MWD, and showed prominent procedural success. Large scale 
      RCTs comparing the TEER devices are needed to strengthen the present findings.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Rehan, Syeda Tayyaba
AU  - Rehan ST
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Eqbal, Farea
AU  - Eqbal F
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Ul Hussain, Hassan
AU  - Ul Hussain H
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Ali, Eman
AU  - Ali E
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Ali, Abraish
AU  - Ali A
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Ullah, Irfan
AU  - Ullah I
AD  - Kabir Medical College, Gandhara University, Peshawar, Pakistan.
FAU - Ullah, Waqas
AU  - Ullah W
AD  - Thomas Jefferson University Hospitals, Philadelphia, PA.
FAU - Ahmed, Jawad
AU  - Ahmed J
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Brailovsky, Yevgeniy
AU  - Brailovsky Y
AD  - Thomas Jefferson University Hospitals, Philadelphia, PA.
FAU - Rajapreyar, Indranee N
AU  - Rajapreyar IN
AD  - Thomas Jefferson University Hospitals, Philadelphia, PA.
FAU - Asghar, Muhammad Sohaib
AU  - Asghar MS
AD  - Mayo Clinic, Rochester, MN. Electronic address: sohaib_asghar123@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20230829
PL  - Netherlands
TA  - Curr Probl Cardiol
JT  - Current problems in cardiology
JID - 7701802
SB  - IM
MH  - Humans
MH  - *Tricuspid Valve Insufficiency/surgery/etiology
MH  - Treatment Outcome
MH  - *Heart Valve Prosthesis Implantation/adverse effects
MH  - Cardiac Catheterization/adverse effects
MH  - Echocardiography
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/09/01 00:41
MHDA- 2023/12/17 09:43
CRDT- 2023/08/31 19:22
PHST- 2023/08/22 00:00 [received]
PHST- 2023/08/23 00:00 [accepted]
PHST- 2023/12/17 09:43 [medline]
PHST- 2023/09/01 00:41 [pubmed]
PHST- 2023/08/31 19:22 [entrez]
AID - S0146-2806(23)00472-3 [pii]
AID - 10.1016/j.cpcardiol.2023.102055 [doi]
PST - ppublish
SO  - Curr Probl Cardiol. 2024 Jan;49(1 Pt B):102055. doi: 
      10.1016/j.cpcardiol.2023.102055. Epub 2023 Aug 29.